All In Biotech

Drug Trial Radar · NCT02458729

The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis

The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis

Last checked: Nov 20, 2026Latest source record: Jun 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

294

Actual

Start

Aug 2012

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Chang Gung Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study was to conduct a prospective, randomized, double-blind study and assess the efficacy of and safety for thromboprophylaxis of rivaroxaban in total knee arthroplasty patients when tranexamic acid is used for bleeding prophylaxis.

Conditions

  • Osteoarthritis, Knee

Interventions

  • Tranexamic Acid 5%,5ml/amp (intraoperative)Drug

    tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet

  • Tranexamic Acid 5%,5ml/amp (3 hours after operation)Drug

    tranexamic acid 1g administered intravenously 3 hours after operation

  • 0.9% Normal Saline (intraoperative)Drug

    0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet

  • 0.9% Normal Saline (3 hours after operation)Drug

    0.9% Normal Saline 20ml administered intravenously 3 hours after operation

  • rivaroxaban (10mg)Drug

    Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of any deep-vein thrombosis, non-fatal pulmonary embolism, or all-cause mortalityTime frame: within 15 days after surgery (2 days after the last dose of rivaroxaban )
  2. Incidence of major bleeding after the first dose of rivaroxaban and all death related to postoperative bleedingsTime frame: within 15 days after surgery (2 days after the last dose of rivaroxaban )

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Chang Gung Memorial Hospital

    Koahsiung, Taiwan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.